Loading organizations...
Loading organizations...
Developing innovative therapeutic antibodies for cancer treatment.
Immune-Onc Therapeutics has raised $138.0M across 4 funding rounds.
Immune-Onc Therapeutics has raised $138.0M in total across 4 funding rounds.
Immune-Onc Therapeutics has raised $138.0M in total across 4 funding rounds.
Immune-Onc Therapeutics's investors include Proxima Ventures, The Leukemia & Lymphoma Society, WuXi Healthcare Ventures, Dave Chenn, Northern Light Venture Capital, Octagon Capital, Sphera Healthcare, Vivo Capital, Stanford.
Immune-Onc Therapeutics has raised $138.0M across 4 funding rounds. Most recently, it raised $25.0M Series B Extension in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 5, 2023 | $25.0M Series B Extension | Proxima Ventures, The Leukemia & Lymphoma Society, WuXi Healthcare Ventures | |
| Mar 30, 2021 | $73.0M Series B | Dave Chenn | Northern Light Venture Capital, Octagon Capital, Sphera Healthcare, The Leukemia & Lymphoma Society, Vivo Capital |
| Sep 18, 2018 | $33.0M Series B | Northern Light Venture Capital, Stanford, Vivo Capital | |
| Sep 6, 2016 | $7.0M Series A |